Advertisement

Topics

UPDATE 3- Eylea helps Regeneron smash profit estimates

12:21 EDT 3 Aug 2017 | Topix

Regeneron Pharmaceuticals Inc's quarterly profit handsomely beat estimates on strong demand for its flagship Eylea drug, prompting the U.S. drugmaker to raise its full-year growth forecast for the eye treatment. Sales of Eylea, which is used to treat macular degeneration and other eye disorders that cause age-related vision loss, came in at $919 million and beat analysts' estimates, helped by higher demand as the U.S. population ages.

Original Article: UPDATE 3- Eylea helps Regeneron smash profit estimates

NEXT ARTICLE

More From BioPortfolio on "UPDATE 3- Eylea helps Regeneron smash profit estimates"

Quick Search
Advertisement
 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...